Loading...
Loading...
ORTX| Name | Value |
|---|---|
| Revenues | 4.4M |
| Cost of Revenue | 1.1M |
| Gross Profit | 3.2M |
| Operating Expense | 35.7M |
| Operating I/L | -32.4M |
| Other Income/Expense | -18.7M |
| Interest Income | 0.2M |
| Pretax | -51.1M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -50.9M |
Orchard Therapeutics plc is a biopharmaceutical company specializing in the development of gene therapies for rare and life-threatening diseases. The company's gene therapy approach involves transforming a patient's hematopoietic stem cells into a gene-modified cellular drug product, offering a potential one-time treatment for various conditions. Their product portfolio includes Strimvelis for adenosine deaminase-severe combined immunodeficiency (ADA-SCID) and a range of clinical development and preclinical programs targeting diseases such as metachromatic leukodystrophy, Wiskott-Aldrich syndrome, chronic granulomatous disease, and beta-thalassemia.
